Efficacy of AR-L 115 BS on Hemodynamics, Contractility, and Myocardial Oxygen Consumption in Man

  • M. Oeff
  • R. Schröder

Abstract

In search of new drugs with positive isotropic and vasodilatory effects for treating chronic congestive heart failure, the imidazole derivative AR-L 115 BS (2-[(2-methoxy-4-methylsulfinyl)-phenyl]-1H-imidazo [4, 5-b]pyridine) was developed. It combines the following effects: high direct cardiac efficacy, a distinctly higher therapeutic range than digitalis glycosides, no substantial increase in the heart rate, long biological half life, and good intestinal reabsorption.

Keywords

Lactate Argon Phenyl Pyridine Radionuclide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Achenbach C, Hauswirth O, Roskothen R, Ziskoven R (1981) Effects of AR-L 115 BS on the electrophysiological and contractile properties of sheep cardiac fibres. Drug Res 31 /1: 171Google Scholar
  2. 2.
    Chatterjee K, Matloff JM, Swan HJC, Ganz W, Kaushik VS, Magnusson P, Henis MM, Forrester JS (1975) Abnormal regional metabolism and mechanical function in patients with ischemic heart disease. Circulation 52: 390PubMedGoogle Scholar
  3. 3.
    Dämmgen J, Kadatz R, Diederen W (1981) Action of AR-L 115 BS on myocardial oxygen consumption, cardiac performance and vascular resistance and capacitance. Drug Res 31 /1: 151Google Scholar
  4. 4.
    Diederen W, Kadatz R (1981) Effects of AR-L 115 BS, a new cardiotonic compound, on cardiac contractility, heart rate and blood pressure in anaesthetized and conscious animals. Drug Res 31 /1: 146Google Scholar
  5. 5.
    Diederen W, Weisenberger H (1981) Studies on the mechanism of the positive-inotropic action of AR-L 115 BS, a new cardiotonic drug. Drug Res 31 /1: 177Google Scholar
  6. 6.
    Hauf GF, Bubenheimer P, Roskamm H (1981) The acute effect of a new positive inotropic agent (AR-L 115 BS) on cardiac hemodynamics and contractility in patients with severe chronic congestive heart failure. Drug Res 31 /1: 253Google Scholar
  7. 7.
    Heiss HW, Barmeyer J, Wink K, Huber G, Hagemann G, Beiter G, Keul J, Reindell H (1975) Durchblutung und Substratumsatz des gesunden menschlichen Herzens in Abhängigkeit vom Trainingszustand. Verh Dtsch Ges Kreislaufforsch 41: 247PubMedGoogle Scholar
  8. 8.
    Heilige G, Baller D, Ensink FBM, Zipfel J, Wolpers HG, Bretschneider HJ (1981) Effects of AR-L 115 on hemodynamics, myocardial oxygen consumption and cardiac pumping efficiency. Drug Res 31 /1: 155Google Scholar
  9. 9.
    Herzig JW, Feile K, Rüegg JC (1981) Activating effects of AR-L 115 BS on the Ca`* sensitive force, stiffness and unloaded shortening velocity (Vmax) in isolated contractile structures from mammalian heart muscle. Drug Res 31 /1: 188Google Scholar
  10. 10.
    Hockerts TH, Höcht B, Broil R, Trenkel K, Sieber J, Kilian A, Brendle B (1981) Die Wirkung von AR-L 115 BS auf die Kontraktionsdynamik des isolierten metabolisch unterstützten Hundeherzens. Drug Res 31 /1: 157Google Scholar
  11. 11.
    Klein G, Sauer E, Bauer R, Wirtzfeld A, Sebening H (1981) The comparison of the effects of AR-L 115 BS and dobutamine in patients with severe cardiac failure. Drug Res 31 /1: 257Google Scholar
  12. 12.
    Kramer W, Thormann J, Bitter C, Schlepper M (to be published) Aktivitätsprofil von AR-L 115 bei Herzgesunden: Wirkungsbeeinflussung durch Ca*’-Antagonisten (Verapamil). Verh Dtsch Ges Inn Med 69Google Scholar
  13. 13.
    Nguyen-Duong H, Rüdel R, Voss V (1981) Effects of AR-L 115 BS on arterial and venous muscle tone in vitro. Drug Res 31 /1: 197Google Scholar
  14. 14.
    Puschmann S, Kirkeeide RL, Nienaber C, Schaper W (1981) Wirkung von AR-L 115 auf die Pumpfunktion des linken Ventrikels mit und ohne Beta-und Calcium-Blockade ( Abstr ). Z Kardiol 70: 271Google Scholar
  15. 15.
    Schrader J (1981) Interaction of AR-L 115 BS with Isoprenaline on hemodynamic parameters in the isolated guinea pig heart. Drug Res 31 /1: 183Google Scholar
  16. 16.
    Sigmund-Duchanova H, Baller D, Bretschneider Hi, Prennschütz-Schützenau H, Piesker KH, Vennebusch H, Zipfel J, Heilige G (1979) Experimental validation of methods for the measurement of coronary sinus blood flow in man. Basic Res Cardiol 74: 277CrossRefGoogle Scholar
  17. 16.
    Sonnenblick EH, Ross J, Braunwald E (1968) Oxygen consumption of the heart. Newer concepts of its multifactoral determination. Am J Cardiol 22: 328PubMedCrossRefGoogle Scholar
  18. 18.
    Stauch M, Nechwatal W (1981) Effects of AR-L 115 BS on hemodynamics and contractility of the heart in cardiac patients. Drug Res 31 /1: 267Google Scholar
  19. 19.
    Tauchert M, Kochsiek K, Heiss HW, Rau G, Bretschneider HJ (1971) Technik der Organdurchblutungsmessung mit der Argon-Methode. Kreislaufforsch 60: 871Google Scholar
  20. 20.
    Thormann J, Kramer W, Schlepper M (1980) AR-L 115: A new non-glycosidic, non-adrenergic cardiotonic agent, hemodynamic proof for its effectiveness both intravenously and by oral application. Circulation [Suppl III162: III - 233Google Scholar
  21. 21.
    Thormann J, Kramer W, Schlepper M (1981) A new non-glycoside, non-adrenergic cardiotonic agent AR-L 115 BS. Drug Res 31 /1: 273Google Scholar
  22. 22.
    Thormann J, Kramer W, Schlepper S (1981) AR-L 115 induzierte Änderungen der Hämodynamik, des koronaren Blutflusses und des Energiemetabolismus bei Patienten mit koronarer Herzerkrankung. Z Kardiol 70: 385PubMedGoogle Scholar
  23. 23.
    Trube G, Trautwein W (1981) Experiments with AR-L 115 BS on skinned cardiac fibers. Drug Res 31 /1: 185Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • M. Oeff
  • R. Schröder

There are no affiliations available

Personalised recommendations